Pre-exposure prophylaxis (PrEP) is a promising intervention to prevent HIV acquisition, with
benefits both to the individual and to population-level health. PrEP is an opportunity to …

Introduction Oral pre‐exposure prophylaxis (Pr EP) for HIV prevention has been proven to
significantly reduce new HIV infections yet scale‐up has been slow. As contexts continue to …

Background No data are available on the feasibility of pre-exposure prophylaxis (PrEP)
delivered by trained key population (KP) community health workers. Herein we report data …

Introduction: Questions remain whether HIV pre-exposure prophylaxis (PrEP) can be
translated into a successful public health intervention, leading to a decrease in population …

Pre-exposure prophylaxis (PrEP) for HIV prevention is recommended by the WHO as part of
a comprehensive HIV prevention package for those at substantial risk of HIV infection [1] …

Background: Tenofovir disoproxil fumarate coformulated with emtricitabine (TDF/FTC) was
shown to be effective in preventing HIV acquisition when used for pre-exposure prophylaxis …

Methods: Epidemiological and costing models estimated the one-year costs and outcomes
associated with PrEP use in 3 scenarios. PrEP uptake was estimated for younger (aged 18 …

Background HIV pre-exposure prophylaxis (PrEP) has likely contributed to large decreases
in HIV incidence among men who have sex with men (MSM) in several major cities. Berlin …

The US Food and Drug Administration (FDA) approved oral daily tenofovir/emtricitabine
(Truvada) for pre‐exposure prophylaxis of human immunodeficiency virus (HIV) infection in …

There have been two key successful major biomedical interventions to prevent HIV
transmission over the past decade: treatment as prevention (TasP) and preexposure …